The company said that TactiCath was granted CE mark for atrial fibrillation (AF) and supraventricular tachycardia (SVT) indications in 2009. The company claims that it is the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during cardiac ablation procedures. Its clinical utility is supported by strong, acute and chronic evidence.
Marlou Janssen, global vice president, marketing and sales CRM at Biotronik, said: “We expect the new partnership between Endosense and Biotronik to boost the commercial adoption of the TactiCath. The extensive clinical study and initial clinical use of the TactiCath have proven its potential to improve the efficacy, safety and reproducibility of catheter ablation procedures, an achievement that is consistent with our commitment to drive positive change in clinical practice. The technology and the Swiss engineering quality match well with our corporate strategy for quality and innovation. We look forward to joining forces to bring this great innovation to market.”
Eric Le Royer, president and CEO of Endosense, said: “We expect the new partnership between Endosense and Biotronik to boost the commercial adoption of the TactiCath. Biotronik has all the attributes to contribute to this success with shared values, a proven track record and a very established presence in the market. Our partnership will produce a major step forward in the area of cardiac ablation, as we will address the unmet need of absolute force control in the electrophysiology lab and, by doing so, change clinical practice.”
